Takeda Pharmaceutical
277 hedge funds and large institutions have $829M invested in Takeda Pharmaceutical in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 94 increasing their positions, 68 reducing their positions, and 33 closing their positions.
267% more call options, than puts
Call options by funds: $26.5M | Put options by funds: $7.22M
191% more capital inflows, than outflows
Capital inflows: $148M | Capital outflows: $51.1M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 68
6% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 33
0.23% more ownership
Funds ownership: 1.84% → 2.07% (+0.23%)
2% less funds holding
Funds holding: 284 → 277 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Clal Insurance
Tel-Aviv,
Israel
|
+$36.2M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$21.7M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$15.3M |
| 4 |
Goldman Sachs
New York
|
+$8.87M |
| 5 |
LMR Partners
London,
United Kingdom
|
+$8.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.46M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$4.37M |
| 3 |
Millennium Management
New York
|
-$3.4M |
| 4 |
HAP Trading
New York
|
-$3.4M |
| 5 |
Jane Street
New York
|
-$2.57M |
TAK Hedge Fund Activity: Q3 2022 in Review
277 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2022, worth a combined $829M — up 3.6% from $800M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TAK positions and 33 closed out — a net gain of 2 holders — while 94 added to existing stakes and 68 trimmed.
The largest buyer was Clal Insurance, adding an estimated $36.2M. The largest seller was Vanguard Group, cutting an estimated $7.46M.
- 277 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2022, down from 284 in Q2 2022.
- Funds reported $829M of Takeda Pharmaceutical stock for Q3 2022, up 3.6% quarter-over-quarter.
- 35 funds opened new Takeda Pharmaceutical positions in Q3 2022 and 33 closed out, a net change of +2 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2022 was Clal Insurance, an estimated $36.2M added.
- The largest Takeda Pharmaceutical seller in Q3 2022 was Vanguard Group, an estimated $7.46M sold.
Based on aggregated 13F filings for Q3 2022.